sinbaglustat

07/01/2003 - "Even when OGT2378 treatment was initiated 7 days after tumor inoculation, tumor growth was similarly impeded (61 versus 620 mm(3), P < 0.0001), demonstrating an effect on an established tumor. "
07/01/2003 - "treatment with OGT2378 starting 3 days before intradermal tumor inoculation of 4 x 10(4) MEB4 cells, and continuing for 4 weeks, resulted in a 10-fold lower mean tumor volume at the end of treatment (60 versus 538 mm(3), P < 0.0001). "
07/01/2003 - "OGT2378 in this murine model suggests that inhibition of glycosphingolipid synthesis is a promising and now feasible novel therapeutic approach to inhibit tumor progression."
07/01/2003 - "Administered in the diet to C57BL/6 mice, 2500 mg/kg/day OGT2378 was well tolerated in vivo and biologically active, depleting host tissue (hepatic) gangliosides by 82% and tumor gangliosides by >98%. "
07/01/2003 - "inhibitor of glucosylceramide synthesis, the imino sugar OGT2378, inhibits MEB4 melanoma tumor growth in a syngeneic, orthotopic murine model. "

07/01/2003 - "inhibitor of glucosylceramide synthesis, the imino sugar OGT2378, inhibits MEB4 melanoma tumor growth in a syngeneic, orthotopic murine model. "